Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The von Willebrand factor A domain-containing protein 1 (VWA1) is an extracellular matrix protein that belongs to the von Willebrand factor A (VWFA) domain superfamily. It is also known as WARP and is characterized by its high-affinity binding to structural extracellular proteins such as collagen VI and perlecan. VWA1 is predominantly expressed in muscle and peripheral nerve tissues, where it plays a crucial role in maintaining neuromuscular structure and the assembly of the pericellular matrix. Loss-of-function mutations in the VWA1 gene are linked to neuromuscular disorders marked by muscle weakness as well as contributions to congenital craniofacial disorders such as hemifacial microsomia. While VWA1 is structurally and functionally significant in extracellular matrix biology and tissue stability, there are no current indications that it acts as a direct therapeutic target, nor are there approved drugs specifically targeting this protein[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on von Willebrand factor A domain-containing protein 1 (VWA1).